Literature DB >> 18926094

Combined modality therapy of esophageal cancer.

Rosalyn A Juergens1, Arlene Forastiere.   

Abstract

Esophageal cancer is a deadly disease. Only one third of patients with localized disease experience long-term survival. Over the past 20 years, investigators have evaluated neoadjuvant strategies to improve the outcomes of surgical management. Chemotherapy and radiation have been evaluated individually and in combination for preoperative management of patients with localized esophageal cancer. This article provides a critical review of the data on multimodality approaches to the management of esophageal cancer.

Entities:  

Mesh：

Year:  2008        PMID： 18926094     DOI： 10.6004/jnccn.2008.0063

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  11 in total

1.  Accomplishments in 2008 in the management of esophageal cancer.

Authors:  Gary Y Yang; Katja Ott
Journal:  Gastrointest Cancer Res       Date:  2009-09

2.  Clinical T2N0M0 carcinoma of thoracic esophagus.

Authors:  Timothy D Wagner; Nikhil Khushalani; Gary Y Yang
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

3.  MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Authors:  Jochen K Lennerz; Eunice L Kwak; Allison Ackerman; Michael Michael; Stephen B Fox; Kristin Bergethon; Gregory Y Lauwers; James G Christensen; Keith D Wilner; Daniel A Haber; Ravi Salgia; Yung-Jue Bang; Jeffrey W Clark; Benjamin J Solomon; A John Iafrate
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

4.  Decreasing morbidity and mortality in 100 consecutive minimally invasive esophagectomies.

Authors:  Kfir Ben-David; George A Sarosi; Juan C Cendan; Drew Howard; Georgios Rossidis; Steven N Hochwald
Journal:  Surg Endosc       Date:  2011-07-27       Impact factor: 4.584

5.  Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma.

Authors:  Timothy A Platz; Steven J Nurkin; Mei Ka Fong; Adrienne Groman; Leayn Flaherty; Usha Malhotra; Charles M Levea; Sai Yendamuri; Graham W Warren; Hector R Nava; Kilian S May
Journal:  J Gastrointest Oncol       Date:  2013-06

6.  Inhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage checkpoint.

Authors:  Kai Zheng; Yan Li; Shaoxiang Wang; Xiao Wang; Chenghui Liao; Xiaopeng Hu; Long Fan; Qiangrong Kang; Yong Zeng; Xuli Wu; Haiqiang Wu; Jian Zhang; Yifei Wang; Zhendan He
Journal:  Autophagy       Date:  2016-06-16       Impact factor: 16.016

7.  Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models.

Authors:  J D Predina; B Judy; L A Aliperti; Z G Fridlender; A Blouin; V Kapoor; B Laguna; H Nakagawa; A K Rustgi; L Aguilar; E Aguilar-Cordova; S M Albelda; S Singhal
Journal:  Cancer Gene Ther       Date:  2011-08-26       Impact factor: 5.987

Review 8.  Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

Authors:  Phu Tran; Cham Nguyen; Samuel J Klempner
Journal:  Int Neurourol J       Date:  2016-11-22       Impact factor: 2.835

9.  The effectiveness and prognostic factors of radioactive iodine-125 seed implantation for the treatment of cervical lymph node recurrence of esophageal squamous cell carcinoma after external beam radiation therapy.

Authors:  Yuwei Zhang; Zezhou Liu; Yansong Liang; Enli Chen; Hongtao Zhang; Zhen Gao; Juan Wang
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

10.  Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library.

Authors:  Zhe-Feng Zhang; Xue Shan; Yong-Xin Wang; Wei Wang; Shi-Yun Feng; You-Bin Cui
Journal:  J Cardiothorac Surg       Date:  2014-04-29       Impact factor: 1.637
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.